Neurocrine Biosciences (NBIX) said Friday the phase 4 study of its Ingrezza treatment for patients with tardive dyskinesia showed improvements in functional and health-related quality of life measures.

Patients with the movement disorder who received the treatment for eight weeks experienced significant improvements in measures such as mobility, self-case, usual activities, and pain/discomfort, the company said.

In a separate analysis, patients who received the treatment also experienced improvements in Sheehan Disability Scale items, including work/school, social life, and family/home life, the company said.